MetaCap

Clene Inc. (CLNN)

NASDAQ: CLNNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.52+0.02 (+0.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CLNN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$50.69M
EPS (TTM)
-$2.30
52-week range
3.02 – 10.84
Day range
3.30 – 3.60
Volume / Avg
143.56K / 115.06K
Beta
—

52-week range

$3.02$10.84

CLNN stock today

Shares of Clene (CLNN) finished higher on Nov 20 at $3.52, a gain of 0.57% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 67.5% below their 52-week high of $10.84, set on Nov 28, 2025 and 16.6% above the 52-week low of $3.02, near the bottom of the past year's range. CLNN is down 40.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.0%.

Clene has posted a net loss over the last twelve months (EPS of -$2.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Clene

Company profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert Etherington MBA
Headquarters
Salt Lake City, UT
Employees
76
Website
clene.com

Financial highlights

Full financials

In fiscal 2025, Clene generated $200,000 in revenue, down 41.5% from fiscal 2024, its first annual decline since 2024. Clene reported a net loss of $26.2 million, compared with a loss of $39.4 million a year earlier. Gross margin was 78.5% (down from 79.5%) and operating margin -11541.5%.

Clene annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$200.00K$342.00K$654.00K$473.00K$723.00K
Growth-41.52%-47.71%+38.27%-34.58%+250.97%
Net income$-26.17M$-39.40M$-49.50M$-29.92M$-9.74M
EPS (diluted)————$-0.16

Analyst forecast

Forecast

Consensus (5 analysts)

none

Avg. price target

$32.20+814.77%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $20.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.05 vs $-0.46
Surprise
+110.87%

CLNN news

All CLNN news

Clene peers

Health Care sector
CLNN peer companies
CompanyPrice% ChgMarket capCompare
ALDXAldeyra Therapeutics Inc.0.84+16.39%$50.70Mvs CLNN
ACRVAcrivon Therapeutics Inc.1.15-17.86%$49.35Mvs CLNN
LFVNLifevantage Corporation4.15-15.13%$52.63Mvs CLNN
XBITXBiotech Inc.1.73+2.98%$52.74Mvs CLNN
HRTXHeron Therapeutics Inc.0.2525-4.39%$48.04Mvs CLNN
RFLRafael Holdings Inc. Class B0.9197+2.19%$47.99Mvs CLNN
ONCYOncolytics Biotech Inc.0.3501-10.37%$47.66Mvs CLNN
CTORCitius Oncology Inc.0.5035-10.95%$53.25Mvs CLNN

Indexes, lists and sector

Clene stock FAQ

What is Clene's stock price today?

CLNN last traded at $3.52 as of Nov 20, 4:00 PM EST, up 0.57% on the day. Prices are delayed at least 15 minutes.

Does Clene pay a dividend?

No. Clene does not currently pay a regular cash dividend.

Who is Clene's CEO?

Mr. Robert Etherington MBA is the chief executive officer of Clene Inc., which has about 76 employees.

Has CLNN ever split its stock?

Yes. The most recent CLNN stock split was a 1-for-20 split on Jul 11, 2024.

What is the CLNN 52-week high?

The 52-week high for CLNN is $10.84 and the 52-week low is $3.02. The stock is currently 67.5% below its high.

Compare CLNN